| Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer S Peters, DR Camidge, AT Shaw, S Gadgeel, JS Ahn, DW Kim, SHI Ou, ... New England Journal of Medicine 377 (9), 829-838, 2017 | 2287 | 2017 |
| A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1) S Ramalingam, G Goss, R Rosell, G Schmid-Bindert, B Zaric, Z Andric, ... Annals of oncology 26 (8), 1741-1748, 2015 | 125 | 2015 |
| Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study … J Gligorov, B Ataseven, M Verrill, M De Laurentiis, KH Jung, HA Azim, ... European Journal of Cancer 82, 237-246, 2017 | 51 | 2017 |
| Use of the Depression, Anxiety and Stress Scale (DASS-21) questionnaire to assess levels of depression, anxiety, and stress in healthcare and administrative staff in 5 oncology … I Marijanović, M Kraljević, T Buhovac, T Cerić, AM Abazović, J Alidžanović, ... Medical Science Monitor: International Medical Journal of Experimental and …, 2021 | 38 | 2021 |
| A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1). SS Ramalingam, GD Goss, ZG Andric, I Bondarenko, B Zaric, T Ceric, ... Journal of Clinical Oncology 31 (15_suppl), CRA8007-CRA8007, 2013 | 37 | 2013 |
| Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with … S Beslija, N Obralic, H Basic, A Tatarevic, M Naila, M Banjin, A Cardzic, ... Journal of Clinical Oncology 24 (18_suppl), 571-571, 2006 | 36 | 2006 |
| Investigation of IVS14+ 1G> A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-Fluorouracil and capecitabine T Cerić, N Obralić, L Kapur-Pojskić, D Macić, S Bešlija, A Pašić, Š Cerić Bosnian journal of basic medical sciences 10 (2), 133, 2010 | 22 | 2010 |
| Lack of access to targeted cancer treatment modalities in the developing world in the era of precision medicine: real-life lessons from Bosnia A Kurtovic-Kozaric, S Vranic, S Kurtovic, A Hasic, M Kozaric, N Granov, ... Journal of Global Oncology 4, 2018 | 19 | 2018 |
| A clinicopathologic study of invasive apocrine carcinoma of the breast: a single‐center experience D Imamovic, N Bilalovic, F Skenderi, V Beslagic, T Ceric, B Hasanbegovic, ... The Breast Journal 24 (6), 1105-1108, 2018 | 16 | 2018 |
| Galaxy-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma. SS Ramalingam, B Zaric, T Ceric, TE Ciuleanu, JF Spicer, I Bondarenko, ... Journal of Clinical Oncology 32 (15_suppl), TPS8118-TPS8118, 2014 | 15 | 2014 |
| Immunohistochemical expression and prognostic significance of VEGF-C in well-differentiated thyroid cancer S Ceric, T Ceric, N Pojskic, N Bilalovic, J Musanovic, ... Acta Endocrinologica (Bucharest) 16 (4), 409, 2020 | 9 | 2020 |
| The prognostic value of SUVmax of 18F-FDG PET/CT in patients with metastatic colorectal cancer. E Sokolović, T Cerić, Š Cerić, S Bešlija, S Vegar-Zubović, N Bešlić, ... | 8 | 2020 |
| Long-term outcome of GIST patients treated with delayed imatinib therapy A Kurtovic-Kozaric, A Kugic, A Hasic, S Beslija, T Ceric, A Pasic, S Vranic, ... European Journal of Cancer 78, 118-121, 2017 | 8 | 2017 |
| 2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina S Bešlija, Z Gojković, T Cerić, AM Abazović, I Marijanović, S Vranić, ... Bosnian journal of basic medical sciences 21 (2), 120, 2021 | 7 | 2021 |
| Value of positron emission tomography/computed tomography (PET-CT) in suspected non-small cell lung cancer recurrence and impact on patient management N Beslic, A Sadija, T Ceric, R Milardovic, S Ceric, S Cavaljuga Acta Informatica Medica 24 (4), 296, 2016 | 7 | 2016 |
| Advantages of combined PET-CT in mediastinal staging in patients with non-small cell lung carcinoma N Beslic, A Sadija, R Milardovic, T Ceric, S Ceric, A Beganovic, S Kristic, ... Acta Informatica Medica 24 (2), 99, 2016 | 7 | 2016 |
| A single institution randomized trial of taxotere (T) and xelocla (X) given in combination vs. taxotere (t) followed by xelocla (x) after progression as first line chemotherapy … S Beslija, N Obralic, H Basic, A Tatarevic, N Mahic, M Banjin, A Sosevic, ... EJC SUPPLEMENTS 3 (2), 114-114, 2005 | 7 | 2005 |
| 1654P A phase Ib/II study of the dual MDMX/MDM2 inhibitor, ALRN-6924, for the prevention of chemotherapy-induced myelosuppression Z Andric, T Ceric, M Rancic, M Jakopovic, SP Aix, R Ramlau, M Ulanska, ... Annals of Oncology 32, S1166, 2021 | 5 | 2021 |
| AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean … V Todorovic, M Aapro, N Pavlidis, O Arsovski, Y Belkacemi, N Babovic, ... Journal of BU ON.: official journal of the Balkan Union of Oncology, 2019 | 5 | 2019 |
| GALAXY-1: randomized phase II study of docetaxel with or without ganetespib in advanced lung adenocarcinoma results in biomarker sub-groups and all adenocarcinoma patients SS Ramalingam, G Shapiro, V Hirsh, B Zaric, T Ceric, E Poddubskaya, ... J Thorac Oncol 8 (Suppl 2), S139, 2013 | 4 | 2013 |
